Stock data
Larimar Therapeutics, Inc. (LRMR)
Larimar Therapeutics, Inc. (LRMR) reported net income of -US$165.67M for fiscal 2025. The figures below come from the company's SEC filings.
Annual results
Data as of 2025-12-31
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | — | — | -US$172.50M | -US$165.67M | — |
| 2024 | — | — | -US$90.89M | -US$80.60M | — |
| 2023 | — | — | -US$41.76M | -US$36.95M | — |
| 2022 | — | — | -US$36.53M | -US$35.35M | — |
| 2021 | — | — | -US$50.47M | -US$50.64M | — |
Quarterly results
Data as of 2026-06-30
| Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| 2026-06-30 | — | -US$32.78M | — |
| 2026-03-31 | — | -US$29.61M | — |
| 2025-12-31 | — | -US$62.50M | — |
| 2025-09-30 | — | -US$47.71M | — |
| 2025-06-30 | — | -US$26.18M | — |
| 2025-03-31 | — | -US$29.28M | — |
| 2024-12-31 | — | -US$28.82M | — |
| 2024-09-30 | — | -US$15.50M | — |
Sources
- Source: SEC EDGAR company facts
Charts, drawing tools, and the P/E calculator are in the app, free to use.